TransMedics Group is facing significant pressure after Scorpion Capital released a scathing short report on January 10th. The report accuses the transplant-therapy company of engaging in healthcare fraud and indicates plans to petition the FDA to suspend approval for its Organ Care System. These allegations have raised serious concerns among investors and analysts, leading to a reevaluation of the company's
TransMedics Group, Inc. (TMDX) saw its stock price decline by 2.45% on December 12, 2024, closing at $65.71, down from the previous day's close of $67.36. The stock opened at $67.62, which was also the day's high, before dipping to a low of $65.28. The trading volume was 1,296,397 shares, about 72% of the average daily volume. The downward movement was primarily driven by negative analyst actions, including
TransMedics Group, Inc. (TMDX) is experiencing a decline in its stock price today, driven by a series of negative analyst actions and investor sentiment. William Blair recently lowered its Q1 2025 earnings per share estimates for TransMedics, now anticipating a loss of $1.25 per share, down from a previous estimate of a $1.15 loss. This adjustment reflects a more pessimistic outlook on the company's near-te
TransMedics Group, Inc. (TMDX) saw its stock rise by 3.03% to close at $68.26 on December 6, 2024, after opening at $66.85. The stock reached an intraday high of $69.57, driven by a combination of investor sentiment and recent corporate developments. The appointment of Gerardo Hernandez as the new CFO, effective December 2, 2024, has been a focal point for investors, as his extensive experience in the healt
TransMedics Group, Inc. (TMDX) has been a topic of interest on Reddit forums, with users discussing the company's recent performance and potential as a long-term investment. One user noted the company's recent appointment of a new CFO and its missed earnings in the last report, which have contributed to a downward trend in the stock. Despite this, some investors see the current price as a good entry point,
TransMedics Group, Inc. (TMDX) saw its stock plummet by 16.09% to close at $71.44 on December 3, 2024, following a series of disappointing announcements that rattled investor confidence. The stock opened at $77.00 and reached a high of $78.71 before succumbing to selling pressure, hitting a low of $71.25. The trading volume surged to 4,593,831 shares, significantly above the average of 1,651,350, indicating
TransMedics Group, Inc. (TMDX) shares are experiencing a significant decline today following the company's announcement of worse-than-expected full-year 2024 revenue guidance. The company now anticipates revenue in the range of $425 million to $440 million, which has disappointed investors and analysts alike. This guidance comes on the heels of a previous earnings miss, where TransMedics reported third-quar
TransMedics Group has recently narrowed its full-year revenue forecast, which has raised concerns among investors about the company's growth prospects. The adjustment in the financial outlook comes despite the company's projection of substantial revenue growth, indicating that the anticipated growth may not meet previous expectations. This revision has likely contributed to the negative sentiment surroundin
TransMedics Group's shares experienced a significant decline after the company announced a narrowed full-year revenue forecast and a change in its financial leadership. The medtech firm adjusted its revenue expectations for 2024 to a range of $428 million to $432 million, down from the previous range of $425 million to $445 million. This revision comes as analysts had anticipated revenue of approximately $4
TransMedics Group, Inc. (TMDX) saw its stock decline by 1.81% to close at $85.14 on December 2, 2024, with further pressure in after-hours trading, dropping an additional 9.57% to $76.99. The day's downturn was primarily driven by the company's announcement of a narrowed revenue forecast for fiscal year 2024, now expected to be between $428 million and $432 million, slightly below the consensus estimate of
TransMedics Group, Inc. shares are experiencing a significant drop in after-hours trading following the company's announcement of a narrowed revenue forecast for the fiscal year 2024. The company adjusted its revenue expectations to a range of $428 million to $432 million, slightly below the consensus estimate of $432.37 million. This revision has raised concerns among investors about the company's growth p
TransMedics Group, Inc. (TMDX) saw its stock rise by 8.06% to close at $87.11 on November 27, 2024, following a series of positive developments. The stock opened at $81.55 and reached a high of $87.57, with trading volume surpassing the average at 1,718,070 shares. The upward momentum was fueled by a favorable policy change from the U.S. Department of Health and Human Services, which removed clinical resear
TransMedics Group, Inc. (TMDX) shares are experiencing a notable uptick today, driven by positive sentiment from Wall Street analysts and investor optimism. The stock has gained traction following a favorable consensus recommendation from brokerage firms, which currently stands at 1.8, indicating an "Outperform" status. Analysts have set an average one-year price target of $123.00, suggesting a significant
TransMedics Group, Inc. (TMDX) shares are experiencing an uptick today, likely influenced by a recent policy change from the U.S. Department of Health and Human Services (HHS). On November 27, 2024, HHS announced the removal of clinical research requirements for kidney and liver transplants involving HIV-positive donors and recipients. This regulatory update is expected to expand the pool of available organ
TransMedics Group, Inc. (TMDX) shares are experiencing an upward movement today, likely influenced by recent institutional interest. Mutual of America Capital Management LLC has recently acquired a new stake in the company, purchasing 4,995 shares valued at approximately $784,000. This move, along with increased positions by other institutional investors, may be contributing to positive sentiment around the
TransMedics Group, Inc. (TMDX) shares are experiencing a notable uptick today, driven by recent institutional interest. Mutual of America Capital Management LLC has purchased a new stake in the company, acquiring 4,995 shares valued at approximately $784,000, as reported in their latest 13F filing. This move is part of a broader trend, with several other institutional investors and hedge funds increasing th
TransMedics Group, Inc. (TMDX) saw its stock rise by 3.34% to close at $78.58 on November 25, 2024, up from the previous close of $76.04. The stock opened at $77.99 and reached a high of $78.99 during the trading session, with a volume of 1,486,043 shares, which is 94.91% of its average daily volume. The upward movement was primarily driven by positive sentiment in the artificial organs market, which is pro
TransMedics Group, Inc. (TMDX) shares are up 3.50% to $78.70 as of 10:44 am on Monday, compared to its previous close of $76.04 on November 22nd. The stock's rise comes amid a broader positive sentiment in the artificial organs market, which is projected to grow significantly over the coming years. According to a report released on November 25th, the artificial organs market is expected to reach a value of
TransMedics Group, Inc. (TMDX) shares are up 3.06% pre market to $78.37 as of 8:32 am on November 25, 2024, from a previous close of $76.04. The stock's rise comes after Thrivent Financial for Lutherans disclosed a new stake in the company, acquiring 26,196 shares valued at approximately $4,113,000 during the third quarter, as per its latest 13F filing with the SEC. This acquisition adds to the interest fro
TransMedics Group, Inc. (TMDX) saw its stock price decline by 4.16% to close at $76.04 on November 22, 2024, following a downgrade from Needham & Company LLC. The firm shifted its rating from "Buy" to "Hold," citing increased competition from companies like OrganOx and Paragonix Technologies, as well as a slowdown in sequential growth. This downgrade, coupled with a pessimistic forecast from Piper Sandler,